XOMA Royalty Corp
XOMAP
Company Profile
Business description
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Contact
Sector
Healthcare
Stock type
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,316.70 | 98.30 | -1.17% |
| CAC 40 | 7,274.48 | 19.89 | -0.27% |
| DAX 40 | 19,884.75 | 85.11 | -0.43% |
| Dow JONES (US) | 42,840.26 | 498.02 | 1.18% |
| FTSE 100 | 8,084.61 | 20.71 | -0.26% |
| HKSE | 19,720.70 | 31.81 | -0.16% |
| NASDAQ | 19,572.60 | 199.83 | 1.03% |
| Nikkei 225 | 38,701.90 | 111.68 | -0.29% |
| NZX 50 Index | 12,904.11 | 149.96 | 1.18% |
| S&P 500 | 5,930.85 | 63.77 | 1.09% |
| S&P/ASX 200 | 8,067.00 | 101.20 | -1.24% |
| SSE Composite Index | 3,368.07 | 1.96 | -0.06% |